Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Latest news on PROMIS NEUROSCIENCES, INC.
06/24ProMIS Neurosciences announces adjournment and change of location of annual m..
GL
06/17ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant..
GL
05/28ProMIS Neurosciences and collaborative team receive Supercluster Award suppor..
GL
05/21PROMIS NEUROSCIENCES : Chairman's Update details new programs from expanded use ..
AQ
05/20PROMIS NEUROSCIENCES : and BC Neuroimmunology expand collaboration to develop an..
AQ
05/20PROMIS NEUROSCIENCES : Chairman's Memorandum, May 20, 2020
PU
05/20ProMIS Neurosciences Chairman's Update details new programs from expanded use..
GL
05/19ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop a..
GL
05/13ProMIS Neurosciences Announces First Quarter 2020 Results
GL
05/12ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for deve..
GL
05/06ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved..
GL
04/30ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dement..
GL
04/22PROMIS NEUROSCIENCES : commends Biogen for clarifying aducanumab regulatory fili..
AQ
04/15ProMIS Neurosciences announces collaboration to develop serological test to a..
GL
04/10PROMIS NEUROSCIENCES : Journal of the American Academy of Neurology Publishes Pr..
AQ
04/09PROMIS NEUROSCIENCES : Journal of the American Academy of Neurology Publishes Pr..
AQ
04/09Journal of the American Academy of Neurology Publishes ProMIS Neurosciences' ..
GL
04/07ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
GL
03/24PROMIS NEUROSCIENCES : Announces approval for warrant repricing
AQ
03/18ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
GL
02/27PROMIS NEUROSCIENCES : initiates Natural History Study of Blood-Based Biomarkers..
AQ
02/26ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarker..
GL
02/25ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Ex..
GL
02/11ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Inve..
GL
02/06ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
GL
01/29ProMIS Neurosciences Data for Alzheimer's Disease Program Targeting Tau Accep..
GL
01/16PROMIS NEUROSCIENCES : Appoints Dr. Jose Luis Molinuevo to its Scientific Adviso..
AQ
01/15PROMIS NEUROSCIENCES : Appoints Dr. José Luis Molinuevo to its Scientific Adviso..
PU
01/15ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advis..
GL
01/09ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation F..
GL
01/08ProMIS Neurosciences issues Chairman's Update detailing positive outlook for ..
GL
01/02PROMIS NEUROSCIENCES : Completes Second Closing of Private Placement
AQ
2019PROMIS NEUROSCIENCES : Completes Second Closing of Private Placement
AQ
2019ProMIS Neurosciences' Alzheimer's disease program takes on renewed significan..
GL
2019PROMIS NEUROSCIENCES : Aducanumab is good; next generation Alzheimer's disease t..
AQ
2019PROMIS NEUROSCIENCES : Completes First Closing of Private Placement
AQ
2019ProMIS Neurosciences Announces Third Quarter 2019 Results
GL
2019ProMIS Neurosciences Undertaking $6.5M Private Placement
GL
2019PROMIS NEUROSCIENCES : outlines best-in-class approach to amyloid-beta-targeting..
PR
2019ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targetin..
GL
2019PROMIS NEUROSCIENCES : issues Chairman's update memorandum and white paper on Al..
PR
2019ProMIS Neurosciences advances ALS program selectively targeting toxic form of..
GL
2019ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxi..
GL
2019PROMIS NEUROSCIENCES : advances Alzheimer's disease program targeting neurotoxic..
PR
2019PROMIS NEUROSCIENCES : Identifies Novel Antibody Candidates for Multiple System ..
AQ
2019ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at ..
GL
2019ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference
GL
2019PROMIS NEUROSCIENCES : to Present at HC Wainwright Investment Conference
AQ
2019PROMIS NEUROSCIENCES : Appoints Internationally Recognized Researcher in Alzheim..
PR
2019ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzhei..
GL
2019ProMIS Neurosciences Announces Second Quarter 2019 Results
GL
2019PROMIS NEUROSCIENCES : Announces Results of Annual Meeting of Shareholders
AQ
2019ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
GL
2019PROMIS NEUROSCIENCES : Highlights Data for PMN310 at AAIC 2019
AQ
2019ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association Internat..
GL
2019PROMIS NEUROSCIENCES : to Present Data at 2019 Alzheimer's Association Internati..
PR
2019PROMIS NEUROSCIENCES : to Present Data at 2019 Alzheimer's Association Internati..
AQ
2019PROMIS NEUROSCIENCES' : Data for Alzheimer's Disease Clinical Candidate PMN310 P..
PR
2019ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 ..
GL
2019PROMIS NEUROSCIENCES' : PMN310 Shows Greater Therapeutic Potential vs. Other Amy..
PR
2019ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Am..
GL
2019ProMIS Neurosciences Closing Private Placement
GL
2019ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warr..
GL
2019PROMIS NEUROSCIENCES : Presents Lead Program for Alzheimer's Disease at Prestigi..
PR
2019ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestig..
GL
2019PROMIS NEUROSCIENCES' : Eugene Williams to Present at JLABS' Conference on Innov..
PR
2019ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Inno..
GL
2019PROMIS NEUROSCIENCES : Identifies Novel Antibodies for Alzheimer's Disease with ..
PR
2019PROMIS NEUROSCIENCES : Announces First Quarter 2019 Results
PR
2019ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
GL
2019ADUCANUMAB FAILURE : Selectivity for the Toxic Oligomer is Essential to Treating..
GL
2019ADUCANUMAB FAILURE : Selectivity for the Toxic Oligomer is Essential to Treating..
PR
2019PROMIS NEUROSCIENCES : to Present Data for Potential Best-in-Class Antibody Cand..
PR
2019ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
GL
2019PROMIS NEUROSCIENCES : Adds Pharmaceutical Leader Timothy Rothwell to Board of A..
PR
1  2  3Next
Upcoming event on PROMIS NEUROSCIENCES, INC.